BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2467806)

  • 1. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours.
    Horwich A; Brada M; Nicholls J; Jay G; Hendry WF; Dearnaley D; Peckham MJ
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):177-84. PubMed ID: 2467806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.
    Lewis CR; Fossà SD; Mead G; ten Bokkel Huinink W; Harding MJ; Mill L; Paul J; Jones WG; Rodenburg CJ; Cantwell B
    Ann Oncol; 1991 Mar; 2(3):203-11. PubMed ID: 1710482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up.
    Dearnaley DP; Horwich A; A'Hern R; Nicholls J; Jay G; Hendry WF; Peckham MJ
    Eur J Cancer; 1991; 27(6):684-91. PubMed ID: 1712606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The UK Children's Cancer Study Group: testicular malignant germ cell tumours 1979-1988.
    Huddart SN; Mann JR; Gornall P; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendsus KR
    J Pediatr Surg; 1990 Apr; 25(4):406-10. PubMed ID: 1691781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
    Price P; Hogan SJ; Bliss JM; Horwich A
    Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
    Fosså SD; Paluchowska B; Horwich A; Kaiser G; de Mulder PH; Koriakine O; van Oosterom AT; de Prijck L; Collette L; de Wit R;
    Br J Cancer; 2005 Nov; 93(11):1209-14. PubMed ID: 16251877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current optimum management of anaplastic germ cell tumours of the testis and other sites.
    Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Crawford SM; Holden L
    Br J Urol; 1986 Jun; 58(3):307-14. PubMed ID: 2424538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
    de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
    Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
    Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
    J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin combination chemotherapy for advanced germ-cell testicular tumours.
    Taylor RE; Duncan W; Davey P; Munro AJ; Cornbleet MA
    Br J Urol; 1985 Oct; 57(5):567-73. PubMed ID: 2415203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies.
    Mann JR; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendszus KR
    Cancer; 1989 May; 63(9):1657-67. PubMed ID: 2467734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis.
    Horwich A; Peckham MJ
    Cancer Treat Rep; 1986 Nov; 70(11):1329-31. PubMed ID: 2429765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
    de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
    Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours.
    Anthoney DA; McKean MJ; Roberts JT; Hutcheon AW; Graham J; Jones W; Paul J; Kaye SB
    Br J Cancer; 2004 Feb; 90(3):601-6. PubMed ID: 14760371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of advanced testicular teratoma.
    Peckham MJ; Horwich A; Easton DF; Hendry WF
    Br J Urol; 1988 Jul; 62(1):63-8. PubMed ID: 2457402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis.
    Germá Lluch JR; Seguí Palmer MA; Climent Durán MA; Blanco Guerrero R; Fernández Sagarra A; Villavicencio H; Solé Balcells FJ
    Eur Urol; 1992; 21(4):287-93. PubMed ID: 1333957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tumour marker regression rate following chemotherapy for malignant teratoma.
    Horwich A; Peckham MJ
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1463-70. PubMed ID: 6209145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.